Monoclonal antibody from AstraZeneca lowers risk for serious COVID-19, company says

An experimental drug developed by AstraZeneca reduces the risk for serious illness or death from COVID-19, company officials announced Monday.

Share on FacebookEmail this to someoneShare on Google+Tweet about this on TwitterPrint this pageShare on LinkedInShare on StumbleUponShare on TumblrShare on RedditFlattr the authorPin on PinterestBuffer this pageDigg this